FDA 483 - Novacyl Roussillon - July 04, 2014

Novacyl, an API manufacturer in Roussillon, France, was cited for significant deficiencies during an FDA inspection. The observations primarily concern inadequate investigations into out-of-specification events, lack of equipment qualification, and insufficient calibration and monitoring procedures for environmental controls. These issues indicate a failure to maintain proper quality control and documentation practices.